COMPLICATIONS OF CHRONIC KIDNEY DISEASE · 2012-01-26 · Management of Anemia in CKD Table 2...
Transcript of COMPLICATIONS OF CHRONIC KIDNEY DISEASE · 2012-01-26 · Management of Anemia in CKD Table 2...
COMPLICATIONSOF CHRONIC
KIDNEY DISEASE
CO-MANAGEMENT OF CKDModule 3 | Course Notes
Supported and certifi ed by:
MALAYSIAN SOCIETYOF NEPHROLOGY
Malaysian FamilyMedicine Specialist
Association
module3.indd 1module3.indd 1 1/25/12 5:39 PM1/25/12 5:39 PM
module3.indd 2module3.indd 2 1/25/12 5:39 PM1/25/12 5:39 PM
CONTENTS PAGE
Renal Anemia 4
Criteria for anemia 4
Prevalence 5
Causes of anemia 6
Investigations for anemia 6
Management of anemia 9
Complications of anemia on CKD 10
Malnutrition 11
Cardiovascular disease in CKD 12
Bone disease 13
Managing bone abnormalities 14
Managing hyperphosphatemia 15
Treatment of abnormal parathyroid hormone 16
Table of Contents
module3.indd 3module3.indd 3 1/25/12 5:39 PM1/25/12 5:39 PM
4
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
Renal Anemia
Anemia is an expected feature of chronic kidney disease (CKD) once the glomerular fi ltration rate (GFR) drops below 60 mL/minute.1 The relation of anemia to CKD is due to the production of erythropoietin (EPO) by the kidneys. EPO is the hormone that stimulates blood cell production in the bone marrow. In CKD, the production of EPO is below the normal levels. The severity of anemia in patients with CKD is related to both the degree of loss of GFR and the cause of kidney disease.
Criteria for anemia
The World Health Organization (WHO) criteria for hemoglobin (Hb) and hematocrit (Hct) levels (sea level) corresponding to anemia is shown in Table 1 below. They also provide corresponding levels for those who live at higher altitudes 2 generally, Hb concentration can be expected to increase by about 0.6 g/dL in women and 0.9 g/dL in men for each 1,000 m of altitude above sea level.3
The kidney disease outcomes quality initiative (KDOQI) Clinical Practice Guidelines state that a diagnosis of anemia should be made and further evaluation should be undertaken at Hb concentrations less than 13.5 g/dL in adult males and less than 12.0 g/dL in adult females.3
Differences between the KDOQI recommendation and the WHO defi nition arise from differences in the data source for the general population: the WHO defi nition is based on sparse data obtained prior to 1968, whereas the defi nition proposed in the current guidelines is based on the more recent national health and nutrition examination survey (NHANES) III data.
There are several reasons why Hb is a more accurate, and hence a better measure of anemia than Hct:1. Measurement of hemoglobin gives an absolute value and, unlike hematocrit, is not affected
greatly by shifts in plasma water2. Hemoglobin levels are directly affected by lack of erythropoietin production from the
kidney and thus serve as a more precise measurement of erythropoiesis.
Table 1. Hb and Hct levels below which anemia is present in a populationa
Age or gender group Hemoglobin Hematocrit
g/dL mmol/l l/l
Children 6–59 months 110 6.83 0.33
Children 5–11 years 115 7.13 0.34
Children 12–14 years 120 7.45 0.36
Non-pregnant women(above 15 years of age)
120 7.45 0.36
Pregnant women 110 6.83 0.33
Men (above 15 years of age) 130 8.07 0.39a Conventional conversion factors: 100 g hemoglobin = 6.2 mmol hemoglobin = 0.30 l/l hematocrit.
module3.indd 4module3.indd 4 1/25/12 5:39 PM1/25/12 5:39 PM
5
Prevalence
The reported prevalence of anemia by CKD stage depends largely on the size of the study; whether study participants are selected from the general population, are at high risk for CKD, or are patients already under a physician’s care; what level of Hb is defi ned as constituting anemia; and whether patients do or do not have diabetes.3
A comparison of the results from NHANES III with NHANES IV shows a lower prevalence of anemia for each CKD stage [Figure 1]. In this analysis, anemia was defi ned by WHO criteria (Hb level <12 g/dL in women and <13 g/dL in men).3
In a study done in CKD patients in Saudi Arabia who had not undergone dialysis, the prevalence of anemia in the different stages of CKD was 42%, 33%, 48%, 71%, and 82% in stages 1 to 5, respectively. The prevalence was also elevated for hemoglobin levels below 11 g/dL (the minimum hemoglobin level at which therapy should be initiated with EPO), which is, 21%, 17%, 31%, 49%, and 72%, respectively for stages 1 to 5.4
The purpose of specifying Hb level thresholds to defi ne anemia is to identify patients who are most likely to show pathological processes contributing to a low Hb level and who therefore are most likely to benefi t from further anemia evaluation. This recommendation is made after analysis of patients with CKD before dialysis therapy, those with kidney transplants and those on dialysis therapy. The reviewed literature spanned close to 40 years of investigation up to the year 2000 and described clinical fi ndings on relationships between Hb or Hct level and kidney function.
The majority of available data were derived from studies of small sample size, most of which are cross-sectional studies, or baseline data from clinical trials of variable size and robustness. In 12 of the 21 studies reviewed, there was an association between level of Hb or Hct and the selected measure of kidney function. These studies also demonstrate variability in levels of Hb or Hct at each stage of kidney function, whether assessed by using serum creatinine (SCr) concentration, creatinine clearance (CCr) or estimated GFR (eGFR). However, the consistency of the information provided indicates a trend toward lower Hb levels at lower levels of GFR and variability in Hb levels across GFR levels. The relationship between GFR and prevalence of anemia is determined mostly by the Hb concentration used to defi ne anemia.
Figure 1. Prevalence of anemia by CKD stage
1 2 3 4
80
60
40
20
0
NHANES III NHANES IV
CKD Stage
Prev
alen
ce (%
)
module3.indd 5module3.indd 5 1/25/12 5:39 PM1/25/12 5:39 PM
6
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
Causes of anemia in CKD5
There are several likely factors contributing to anemia in CKD. Unfortunately, little is known about the relative contributions of the different factors and conditions in the early stages of CKD. Blood loss Patients with CKD are at risk of blood loss due to platelet dysfunction. The main cause of
blood loss is dialysis, especially hemodialysis. This loss results in absolute iron defi ciency. Erythropoietin (EPO) defi ciency Considered the most important cause of anemia in CKD
Shortened red blood cell life span The life span of red blood cells is reduced by approximately one third in hemodialysis patients.
Iron defi ciency Iron homeostasis appears to be altered in CKD. For reasons not yet known (perhaps
malnutrition), transferrin levels in CKD are one half to one third of normal levels, diminishing the capacity of the iron-transporting system. This situation is then aggravated by the well known inability to release stored iron from macrophages and hepatocytes in CKD.
Vitamin defi ciencies Diffi cult to determine if this plays a role as most CKD patients are on a multivitamin supplement.
Infl ammation CKD shares several features of the infl ammatory state. The anemia of infl ammation is also
characterized by low serum iron, low transferrin saturation, and impaired release of stored iron, manifested as high serum ferritin.
The “uremic milieu” An overused term that tries to explain the multiple organ dysfunction of CKD.
Investigations for anemia in CKD
Because little is known about the natural history of anemia in patients with CKD, precise information is unavailable to determine the optimum frequency of Hb testing in patients with CKD. The KDOQI Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease recommend measurement of Hb at least annually in patients with CKD.
The importance of identifying patients with anemia in the presence of CKD is 2-fold:A Hb value in the lowest fi fth percentile of the general population may signify the presence
of signifi cant nutritional defi cits, systemic illness or other disorders that warrant attention. Anemia in patients with CKD is a known risk factor for a number of signifi cant adverse
patient outcomes, including hospitalizations, cardiovascular disease (CVD), cognitive impairment and mortality.2
While measuring Hb and diagnosing anemia, care must be taken to assess the normal ranges of the person with respect to factors like altitude, age, race and smoking which have an impact on the Hb values. Anemia in chronic kidney disease should be evaluated and treated (Figure 2).3
module3.indd 6module3.indd 6 1/25/12 5:39 PM1/25/12 5:39 PM
7
Figure 2. Anemia work-up for CKD patients
* indicates that laboratory values are consistent with uncomplicated iron defi ciency
CheckHb
Serumcreatinine>2 mg/dL?
CBC, Indices, Retics:Iron: TIBC, Fe, TSAT,Ferritin; Stool Guaiac
Work-up
No Work-up
Anemianot
corrected
Anemiacorrected:periodicfollow-up
Treat withEpoetin ifindicated
Treat withiron
Normal?Refer for
hematologywork-up
Fedeficiency?*
Yes
Yes
Yes Yes
No
NoNo
<12.5 ( ,Post-menopausal )
<11.0 ( /prepubertal)?
module3.indd 7module3.indd 7 1/25/12 5:39 PM1/25/12 5:39 PM
8
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
Anemia in patients with CKD is not always caused by EPO defi ciency alone. Initial laboratory evaluation therefore is aimed at identifying other factors that may cause or contribute to anemia or lead to erythropoiesis-stimulating agent (ESA) hyporesponsiveness. ESA applies to all agents that augment erythropoiesis through direct or indirect action on the erythropoietin receptor. Some of the ESAs available include epoetin alfa, epoetin beta, and darbepoetin alfa.
Although erythropoietin defi ciency is common among patients with anemia and CKD, other potential causes and potentially contributing disorders should be identifi ed or excluded. The recommended laboratory evaluation provides information regarding the degree and cause of anemia, activity of the erythroid and non-erythroid marrow, as well as assessment of iron stores and iron availability for erythropoiesis.
In particular, clinicians should consider causes of anemia other than erythropoietin defi ciency when: 1. severity of the anemia is disproportionate to the defi cit in renal function; 2. there is evidence of iron defi ciency, or 3. there is evidence of leukopenia or thrombocytopenia.
An evaluation of the cause of anemia should precede initiation of ESA therapy.
In addition to Hb, other reported results of the complete blood count (CBC) may convey important clinical information. Defi ciency of folate or vitamin B12 may lead to macrocytosis, whereas iron defi ciency or inherited disorders of Hb formation (α- or β-thalassemia) may produce microcytosis. Macrocytosis with leukopenia or thrombocytopenia suggests a generalized disorder of hematopoiesis caused by toxins (eg, alcohol), nutritional defi cit (vitamin B12 or folate defi ciency), or myelodysplasia.
In general, the anemia of CKD is normochromic and normocytic; that is, morphologically indistinguishable from the anemia of chronic disease. It is characteristically hypoproliferative: erythropoietic activity is low, consistent with insuffi cient erythropoietin stimulation. While considering this type of anemia, the other types must be ruled out especially those involving the bone marrow diseases and liver and endocrine functions.
The other differential diagnosis for this condition are Aplastic anemia Myelophthisic anemia Myeloid metaplasia Liver disease – Cirrhosis Endocrine disorders – Hyperthyroidism, hypothyroidism, hypoadrenalism,
panhypopituitarism, primary and secondary hyperparathyroidism.
module3.indd 8module3.indd 8 1/25/12 5:39 PM1/25/12 5:39 PM
9
Ma
na
ge
me
nt o
f An
em
ia in
CK
D
Table 2 provides an outline of the key stages of managing anem
ia of CK
D (as m
entioned in the 2011 NIC
E G
uidelines on A
nemia m
anagement in people w
ith chronic kidney disease). 6
Table 2. Overview
of Anem
ia Managem
ent in CK
D
Iron
do
ses
*
Ad
just
ES
Ad
ose
an
dfre
qu
en
cy:
tom
aintain
stable
Hb
betw
een1
0an
d1
2g
/dL
(or
9.5
and
11
.5g
/dLin
child
renu
nd
er2
years)to
keeprate
Hb
increase
betw
een1
and
2g
/dL/m
on
thif
Hb
abo
ve1
1.5
g/d
Lo
rb
elow
10
.5g
/dL
DIA
GN
OS
IS
Isa
ne
mia
du
eto
CK
D?
Co
nsid
ero
ther
causes
ifeG
FR6
0m
l/min
/1.7
3m
2
Co
nsid
er
inv
estig
atin
ga
nd
trea
ting
an
em
iaif:
Hb
11
g/d
LH
b1
0.5
g/d
Lin
child
renu
nd
er2
yearssym
pto
ms
attribu
table
toan
emia
develo
p
De
term
ine
iron
statu
s:Iro
nd
eficiency
anem
ia:d
iagn
osed
wh
enseru
mferritin
<1
00
μg
/linstag
e5
CK
Dco
nsid
eredw
hen
serum
ferritin<
10
0μ
g/lin
stage
3an
d4
CK
DFu
nctio
naliro
nd
eficiency
defin
edb
y:serum
ferritin>
10
0μ
g/lan
deith
er%
HR
C>
6%
(iftest
available),
or
TSAT
<2
0%
(Serum
ferritinis
often
raisedin
CK
D;
interp
retd
iagn
ostic
cut-o
ffvalu
ed
ifferently
than
inn
on
-CK
Dp
atients)
TR
EA
TM
EN
T
Op
timize
iron
statu
s:b
efore
or
wh
enstartin
gESA
sb
efore
decid
ing
wh
ether
tou
seESA
sin
no
n-d
ialysisp
atients
Iron
corre
ction
sho
uld
ma
inta
in*:
serum
ferritin>
20
0μ
g/l
TSAT
>2
0%
(un
lessferritin
>8
00
μg
/l)%
HR
C<
6%
(un
lessferritin
>8
00
μg
/l)R
ev
iew
iron
do
se:
wh
enseru
mferritin
reaches
50
0μ
g/l
(sho
uld
no
trise
abo
ve8
00
μg
/l)
Initia
teE
SA
s:fo
rp
atients
likelyto
ben
efitin
qu
alityo
flife
and
ph
ysicalfun
ction
con
sider
app
rop
riateness
of
ESAu
seif
com
orb
idities
or
pro
gn
osis
neg
ateb
enefit
initiate
ESAtrialif
ben
efitu
ncertain
Ag
ealo
ne
sho
uld
no
tb
ea
determin
ant
for
treating
anem
iao
fC
KD
MA
INT
EN
AN
CE
Ma
inta
iniro
nle
ve
ls*
*:seru
mferritin
20
0–5
00
μg
/linb
oth
hem
od
ialysisan
dn
on
-hem
od
ialysisp
atients
an
de
ithe
r–
TSAT
>2
0%
(un
lessferritin
>8
00
μg
/l),o
r–
%H
RC<
6%(unless
ferritin>
800μg/l)
(inp
racticelikely
toreq
uire
i.v.iro
n)
Mo
nito
r:iro
nstatu
sn
oearlier
than
1w
eekafter
receiving
i.v.iro
nan
dat
intervals
of
4w
eeksto
3m
on
ths
rou
tinely
Hb
every2
–4w
eeks(in
du
ction
ph
ase)o
r1
–3m
on
ths
(main
tenan
cep
hase)
du
ring
ESAth
erapy
Hb
mo
reactively
afterad
justin
gESA
do
sein
clinicalsettin
gag
reedw
ithp
atient
Ad
just
ES
Ad
ose
an
dfre
qu
en
cy:
ifH
bab
ove
11
.5g
/dL
or
belo
w1
0.5
g/d
Lestab
lished
rateo
fch
ang
ein
Hb
,e
g>
1g
/dL/m
on
thIn
vestigate
cause
of
any
un
expected
chan
ge
inH
blevel
Re
vie
wE
SA
use
:if
ESAtrial,
revieweffectiven
essd
iscuss
con
tinu
edu
sew
ithallp
atients
afteran
agreed
interval
Co
rrectio
n:
usu
ally6
00
–10
00
mg
iron
for
adu
ltso
req
uivalen
td
oses
for
child
ren(sin
gle
or
divid
edd
ose
dep
end
ing
on
the
prep
aration
).Treat
patien
tsw
ithfu
nctio
naliro
nd
eficiency
with
i.v.iro
n.
Periton
ealdialysis
and
no
n-d
ialysisp
atients
wh
od
on
ot
respo
nd
too
raliron
willreq
uire
i.v.iro
n.
Inap
pro
priate
circum
stances,
iron
treatmen
tcan
alsob
ead
min
isteredin
the
com
mu
nity.
**
Ma
inte
na
nce
:d
osin
greg
imen
willd
epen
do
nm
od
ality,fo
rexam
ple
hem
od
ialysisp
atients
willreq
uire
the
equ
ivalent
of
50
–60
mg
i.v.iro
np
erw
eek(o
ran
equ
ivalent
do
sein
child
reno
f1
mg
/kg/w
eek).Perito
neald
ialysisan
dn
on
-dialysis
patien
tsw
ho
do
no
tresp
on
dto
oraliro
nw
illrequ
irei.v.
iron
.
module3.indd 9module3.indd 9 1/25/12 5:39 PM1/25/12 5:39 PM
10
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
Management of anemia in CKD starts with the cause for the condition. If all other causes are excluded, treatment of the condition can be initiated with an ESA. The pharmacological agent is usually injected subcutaneously two or three times a week. Patients on hemodialysis who cannot tolerate ESA injections may receive the hormone intravenously during treatment. The intravenous method, however, requires a larger, more expensive dose and may not be as effective. There are several different types of ESAs as shown in Table 2.7
The U.S. Food and Drug Administration (FDA) recommends that patients treated with ESA therapy should achieve a target Hb between 10 and 12 g/dL. Recent studies have shown that raising the Hb above 12 g/dL in people who have kidney disease increases the risk of myocardial infarctions, heart failure, and stroke. People who take ESA injections should have regular tests to monitor their Hb. Any rise in Hb level above 12 g/dL should prompt adjustment of the ESA dose.
Complications of Anemia on CKD
In a normal person, hypoxia serves as a stimulus for the kidneys to produce EPO which in turn stimulates the bone marrow to produce more RBCs and relieves hypoxia. In people with CKD the derangement of this mechanism results in hypoxia and its effects. Another complication is secondary hyperparathyroidism and the development of renal osteodystrophy.
Apart from the CV risk factors induced by CKD, anemia in CKD independently contributes to cardiac disease risk. In a study using data from the North American study of etanercept in chronic heart failure,
it was shown that 12% of these subjects had anemia, with a Hb ≤12 g/dL, and that anemia correlated directly with greater risk of hospitalization and mortality.8
There was a similar “dose-response” relationship in a large single-center study of 2281 subjects admitted to a hospital with heart failure, of which almost half had a Hct less than 37%. In that study, it was shown that each 1% drop in Hct was associated with a 2% rise in mortality.9 There was a 40% greater mortality in subjects with a Hct of 27% compared with a hct of 42%, an increased risk comparable to that of having a left ventricular ejection fraction of 20%.
The community-based study of McClellan and colleagues showed that 14% of hospitalized subjects with heart failure had a Hct ≤ 30%, and 45% had a Hct ≤ 35%.10 In this study, a 1% lesser Hct corresponded to a 1.6% increase in mortality.
Table 2. Currently available erythropoietin stimulating agents (ESAs)
Type of ESA Company
1st generation Epoetin alfa (Eprex) Epoetin beta (Recormon)
Janssen-CilagRoche
2nd generation Darbepoetin alfa (Aranesp) Amgen (not available in Malaysia)
3rd generation Continuous erythropoietin receptor activator (Mircera)
Roche
module3.indd 10module3.indd 10 1/25/12 5:39 PM1/25/12 5:39 PM
11
Anemia is now confi rmed as a risk factor for left ventricular hypertrophy (LVH) in patients on chronic dialysis and patients with chronic renal failure not yet on dialysis.11,12 LVH, in turn, is a risk factor for symptomatic heart disease, including heart failure and sudden death. Thus, heart failure can worsen the kidney function, anemia can result from those two conditions and this in turn stresses the heart, thus forming a vicious cycle.
Malnutrition
Protein-energy malnutrition (PEM) is very common among patients with advanced CKD and those undergoing maintenance dialysis (MD) therapy worldwide. Different reports suggest that the prevalence of this condition varies from roughly 18% to 70% of adult MD patients.13 In adults, the presence of PEM is one of the strongest predictors of morbidity and mortality.
There are many causes of PEM in patients with advanced CKD. These include: inadequate food intake secondary to: anorexia caused by the uremic state altered taste sensation intercurrent illness emotional distress or illness impaired ability to procure, prepare or mechanically ingest foods unpalatable prescribed diets
catabolic response to superimposed illnesses the dialysis procedure itself, which may promote wasting by removing such nutrients
as amino acids, peptides, protein, glucose, water-soluble vitamins and other bioactive compounds, and may promote protein catabolism, due to bioincompatibility.
conditions associated with CKD that may induce a chronic infl ammatory state and may promote hypercatabolism and anorexia
loss of blood due to: gastrointestinal bleeding frequent blood sampling blood sequestered in the hemodialyzer and tubing
endocrine disorders of uremia (resistance to the actions of insulin and IGF-I, hyperglucagonemia, and hyperparathyroidism)
possibly the accumulation of endogenously formed uremic toxins or the ingestion of exogenous toxins.
Notwithstanding the many causes of PEM in patients with CKD, provision of adequate nutrition is a key component of the prevention and treatment of PEM in adults and children receiving MD.
Optimal monitoring of protein-energy nutritional status for MD patients requires the collective evaluation of multiple parameters, particularly using measures that assess different aspects of protein-energy nutritional status.
module3.indd 11module3.indd 11 1/25/12 5:39 PM1/25/12 5:39 PM
12
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
No single measure provides a complete overview of protein-energy nutritional status. Serum albumin is recommended for routine measurement because there is a large body
of literature that defi nes the normal serum albumin values, characterizes the nutritional and clinical factors affecting serum albumin concentrations, and demonstrates the relationship between serum albumin concentrations and outcome.
Body weight, adjusted for height, is proposed because of the clear association between body weight and body fat mass and because body weight is correlated with clinical outcome.
Subjective global nutritional assessment (SGA) is recommended because it gives a comprehensive overview of nutritional intake and body composition, including a rough assessment of both muscle mass and fat mass, and because it is correlated with mortality rates. Assessment of nutrient intake is essential for assessing the probability that a patient will
develop PEM, for evaluating the contribution of inadequate nutrient intake to existing PEM, and for developing strategies to improve protein-energy nutritional status. Also, nutrient intake is correlated with clinical outcome.
Protein Equivalent of Total Nitrogen Appearance normalized to body weight (nPNA) provides an independent and less time-consuming assessment of dietary protein intake (DPI).
Dietary interviews and diaries can be used to assess intake not only of protein and energy but also of a variety of other nutrients as well as the pattern and frequency of meals (information that may aid in identifying the cause of inadequate nutrient intake).
A low predialysis or stabilized serum urea level may indicate a low intake of protein or amino acids.
Others like serum creatinine, serum cholesterol, dual energy X-ray absorptiometry are useful tests to assess protein energy nutritional status.
Cardiovascular disease in CKD
Cardiovascular Disease (CVD) and CVD seem to be lethally synergistic and both are approaching the epidemic level. Far more patients with a GFR below 60 mL/min/1.73 m2 will die from CV causes than progress to end-stage renal disease. Understanding the complex mechanisms underlying the development of CVD among CKD patients is required to begin devising therapy to prevent or reverse this process.14 Observational studies of CVD in CKD are diffi cult to interpret because renal impairment is almost always accompanied by confounding factors. These include the underlying disease process itself (for example, diabetes mellitus and systemic vasculitis) and the complications of CKD, such as hypertension, anemia and infl ammation.
CVD, defi ned as the presence of either congestive heart failure (CHF), ischemic heart disease (IHD), or LVH, is prevalent in cohorts with established CKD (8-40%). The prevalence of hypertension, a major risk factor for coronary artery disease (CAD) and LVH, is high in patients with CKD (87-90%). At least 35% of patients with CKD have evidence of an ischemic event (myocardial infarction or angina) at the time of presentation to a nephrologist. The prevalence of LVH increases at each stage of CKD, reaching 75% at the time of dialysis initiation, and the modifi able risk factors for LVH include anemia and systolic blood pressure, which are also worse at each stage of kidney disease. Even under the care of nephrologists, a change in cardiac status (worsening of heart failure or anginal symptoms)
module3.indd 12module3.indd 12 1/25/12 5:39 PM1/25/12 5:39 PM
13
occurs in 20% of patients. The presence of CVD predicts a faster decline of kidney function and the need for dialysis, after controlling for all other factors including GFR, age, and the presence of LVH.15 A study found that reduced GFR is associated with increased mortality risk in patients with heart failure.16 Signifi cant correlations were observed between eGFR and systolic blood pressure, diastolic blood pressure, age, New York Heart Association class, complications of percutaneous coronary interventions, including bleeding, and major adverse cardiac events.
A study examined the associations between hemoglobin level, kidney function, and risks of death and hospitalization in persons with chronic heart failure between 1996 and 2002 within a large, integrated, healthcare delivery system in northern California and found that compared with those with a GFR > 60 mL/min/1.73 m2, persons with a GFR <45 mL/min/1.73m2 had an increased mortality risk: adjusted HR, 1.39 and 95% CI, 1.34 to 1.44 for 30 to 44; HR, 2.28 and 95% CI, 2.19 to 2.39 for 15 to 29; HR, 3.26 and 95% CI, 3.05 to 3.49 for <15; and HR, 2.44 and 95% CI, 2.28 to 2.61 for those on dialysis.17
Bone disease
Disturbances in mineral and bone metabolism are common in patients with CKD. A large body of evidence indicates that these derangements are associated with increased mortality and morbidity. These patients have bone pain, increased incidence of bone fractures, deformity, myopathy, muscle pain and ruptures of tendons. Hyperphosphatemia also appears to be associated with increased mortality, and elevated blood levels of PTH exert signifi cant adverse effects on the function of almost every organ.
Importantly, the long-term effects of these derangements on soft tissue calcifi cation have become an area of growing concern in the care of CKD patients. Calcifi cation of the lung leads to impaired pulmonary function, pulmonary fi brosis,
pulmonary hypertension, right ventricular hypertrophy and right-side CHF. Calcifi cation of the myocardium, coronary arteries and cardiac valves results in CHF,
cardiac arrhythmias, ischemic heart disease and death. Vascular calcifi cation leads to ischemic lesions, soft-tissue necrosis and diffi culties for
kidney transplantation.
The processes causing disordered mineral metabolism and bone disease have their onset in the early stages of CKD, continue throughout the course of progressive loss of kidney function, and may be infl uenced benefi cially or adversely by the various therapeutic approaches now used. Thus, prevention of the disturbances in mineral and bone metabolism and their management early in the course of CKD are extremely important in improving the quality of life and longevity of CKD patients.The nature and type of bone disease that develops in CKD may vary from one patient to another. Multiple reasons may account for these variations.
The two major types of bone disease that are commonly encountered in patients with CKD are: enhanced bone resorption (osteitis fi brosa) adynamic bone disease
module3.indd 13module3.indd 13 1/25/12 5:39 PM1/25/12 5:39 PM
14
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
Some patients may have one of these types predominantly, whereas others may have a mixed type of bone disease. Mild forms of these derangements in bone metabolism may be observed in the early stages of CKD (Stage 2) and they become more severe as kidney function deteriorates. Osteosclerosis may also occur, and osteoporosis may be encountered.
Managing bone abnormalities19
CKD STAGES 1 and 2
With osteoporosis and/or high risk of fracture, as identified by World Health Organization (WHO) criteria…
Manage as per general population.
CKD STAGE 3
With PTH in the normal range and osteoporosis and/or high risk of fracture, as identified by WHO criteria…
Treat as per the general population.
With biochemical abnormalities of CKD-MBD and low BMD and/or fragility fractures…
Suggest treatment choices taking into account the magnitude and reversibility of the biochemical abnormalities and the progression of CKD, with consideration of a bone biopsy.
CKD STAGES 4–5 DWith biochemical abnormalities of CKD-MBD and low BMD and/or fragility fractures…
Perform additional investition with bone biopsy prior to therapy with antiresorptive agents.
CKD STAGES 1–3TGFR >30 mL/min/1.73 m2
with low BMD
Consider treatment with vitamin D, calcitriol/alphacalcidiol, or bisphosphonates in the first 12 months.
Base treatment choices on presence of CKD-MBD, as indicated by abnormal levels of calcium, phosphorus, PTH, alkaline phosphatases, and 25(OH)D.
Consider bone biopsy to guide treatment, specifically before the use of bisphosphonates due to the high incidence of adynamic bone disease.
There are insufficient data to guide treatment after the first 12 months.
CKD STAGES 4–5TGFR <30 mL/min/1.73 m2
with low BMDSuggest management as for patients with CKD stages 4–5 not on dialysis.
module3.indd 14module3.indd 14 1/25/12 5:39 PM1/25/12 5:39 PM
15
Managing hyperphosphatemia19
DIET PHOSPHATE BINDERS AND OTHER MEDICATIONSDIALYTIC
PHOSPHATE REMOVAL
CKD stages 3–5 and kidney transplant recipients (KTRs) with hyperphos - phatemia
Suggest limiting dietary
phosphate intake
alone or in combination with other treatments
Suggest using phosphate binders, taking into account (NG):• CKD Stage• Presence of other components of CKD-MBD• Concomitant therapies• Side effect profi le
N.A.
CKD stages 3–5 and KTRs with hyperphosphatemia and persistent or recurrent hypercalcemia
Recommend restricting dose of: • Calcium-based phosphate binders and/or• Calcitriol or vitamin D analogue
CKD stages 3–5 and KTRs with hyper-phosphatemia and arterial calcification and/or adynamic bone disease and/or persistently low PTH levels
Suggest restricting the dose of calcium-based phosphate binders
CKD stage 5D
Suggest using phosphate binding agents.Suggest the choice of agent should take into account: • CKD stage• Presence of other components of CKD-MBD• Concomitant therapies• Side effect profi le
Suggest increasing dialytic phosphate
removal in the treatment of
hyperphosphatemia
module3.indd 15module3.indd 15 1/25/12 5:39 PM1/25/12 5:39 PM
16
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
Treatment of abnormal parathyroid hormone19
CKD Stages 3–5 ND
Higher PTH With severe HPT that fails to respond to medical/pharmacological therapy...
Parathyroidectomy is suggested.
If PTH is progressively increasing and remains persistently above the upper limit of assay despite correction of modifi able factors...
Suggest treatment with calcitriol or vitamin D analogs.
If intact PTH is above the upper normal limit of the assay, evaluate for: • Hyperphosphaternia• Hypocalcemia• Vitamin D defi ciency
It is reasonable to correct these abnormalities with any or all of: • Reducing dietary
phosphorus• Phosphate binders• Calcium supplements, and/
or• Native vitamin D
Normal PTH range varies with type of assay. The optimal PTH level is not known.
Lower PTH
CKD Stage 5DSuggestion: Maintain PTH at approximately 2 to 9 times upper normal limit for assay. If PTH changes markedly in either direction within this range, initiate or change therapy to avoid progression to levels outside this range.
Parathyroidectomy is suggested when there is severe HPT and failure to respond to medical/pharmacologic therapy.
Higher PTH IF PTH IS ELEVATED OR RISING
Suggested treating with: Calcitriol, or• Vitamin D analogs, or• Calcimimetics, or• Combination of calcimimetics
and calcitriol or vitamin D analogs
It is reasonable to base initial drug selection on: Levels of serum calcium and phosphorus• Other aspects of CKD-MBD
Adjust calcium or non-calcium-based phosphate binder so that treatments to control PTH do not compromise levels of phosphorus and calcium.
IF PTH FALLS BELOW 2 TIMES THE UPPER LIMIT OR NORMAL
Suggested reducing or stopping: Calcitriol• Vitamin D analogs and/or• Calcimimetics
UPPER/LOWER LIMIT OF NORMAL
Lower PTH
References: 1. Teehan G et al. Anemia 2011;2011:623673. 2. World Health Organization: Iron Defi ciency Anaemia: Assessment, Prevention and Control. Available at http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf. Accessed on 29 June 2011. 3. The KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Available at http://www.kidney.org/professionals/kdoqi/guidelines_anemia/guide2.htm#cpr11. Accessed on 29 June 2011. 4. Shaheen F, et al. Saudi J Kidney Dis Transpl 2011;22 (3):456-463. 5. Nurko S. Cleve Clin J Med 2006;73:289-297. 6. NICE CG114. Anaemia management in people with chronic kidney disease. Available at www.nice.org.uk. Accessed July 28th, 2011. 7. Hayat A, et al. Patient Preference and Adherence 2008;2:195-200. 8. Anand I, et al. Circulation 2004;110:149-154. 9. Kosiborod M, et al. Am J Med 2003;114:112-119. 10. McClellan WM, et al. J Am Soc Nephrol 2002;13:1928-1936. 11. Harnett JD, et al. J Am Soc Nephrol 1994;4:1486-1490. 12. McMahon LP, et al. J Am Soc Nephrol 2004;15:1640-1647. 13. K/DOQI Nutrition Clinical Practice Guidelines. American Journal of Kidney Diseases 2000;35 (6) Supp 2: pp S9-S10. 14. Moody WE, et al. J Hum Hypertens 2011 May 19. [Epub ahead of print] 15. Levin A. Semin Dial 2003;16 (2):101-105. 16. Malyszko J, et al. Isr Med Assoc J 2010;12 (8):489-493. 17. Go AS, at al. Circulation 2006;113 (23):2713-2723. 18. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76 (Suppl 113): S22–S49 19. KDOQI Evaluation and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Bone Guide. Available at ttp://www.kidney.org/professionals/tools/pdf/02-10-390B_LBA_KDOQI_BoneGuide.pdf. Accessed July 28th 2011.
module3.indd 16module3.indd 16 1/25/12 5:39 PM1/25/12 5:39 PM
17
NOTES
module3.indd 17module3.indd 17 1/25/12 5:39 PM1/25/12 5:39 PM
NOTES
18
module3.indd 18module3.indd 18 1/25/12 5:39 PM1/25/12 5:39 PM
19
module3.indd 19module3.indd 19 1/25/12 5:39 PM1/25/12 5:39 PM
Editorial development by UBM Medica Medical Education.The opinions expressed in this publication are not necessarily those of the editor, publisher or sponsor. Any liability or obligation for loss or damage howsoever arising is hereby disclaimed. ©2011 UBM Medica. All rights reserved. No part of this publication may be reproduced by any process in any language without the written permission of the publisher. Enquiries: UBM Medica Sdn Bhd, Level 3A, Luther Centre, No. 6, Jalan Utara, 46200 Petaling Jaya, Selangor, Malaysia. Tel: (603) 7954 2910 | Fax: (603) 7958 7853 | E-mail: [email protected] | Web site: www.ubmmedica.com | MY-ROC-124c
This program is brought about by an educational grant from
module3.indd 20module3.indd 20 1/25/12 5:39 PM1/25/12 5:39 PM